Dopamine D₃agonists

Bibliography

• SOKOLOFF P, GIROS B, MARTRES MP, BOUTHENET ML, SCHWARTZ JC: Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature (1990) 347(6289):146–151.
   PubMed Web of Science ®Google Scholar
• ZABORSZKY L, VADASZ C: The midbrain dopaminergic system: anatomy and genetic variation in dopamine neuron number of inbred mouse strains. Behav. Genet. (2001) 31(1):47–59.
   PubMedGoogle Scholar
• HANTRAYE P: Modeling dopamine system dysfunction in experimental animals. Nucl. Med. Biol. (1998) 25(8):721–728.
   PubMedGoogle Scholar
• SKOOG B, NOGA BR: Dopaminergic control of transmission from group II muscle afferents to spinal neurons in the cat and guinea-pig. Exp. Brain Res. (1995) 105:39–47.
   PubMedGoogle Scholar
• UN SC, KAPLAN J, BURGER CD, FREDRICKSON PA: Effect of pramipexole in treatment of resistant restless legs syndrome. Mayo. Gbh. Proc. (1998) 73:497–500.
   PubMed Web of Science ®Google Scholar
• LIU S, QIAO JT, DAFNY N: D2 dopaminereceptor involvement in spinal dopamine-produced antinociception. Life Sci (1992) 51:1485–1492.
   PubMed Web of Science ®Google Scholar
• MACKENZIE RG, VANLEEUWEN D, PUGSLEY TA etal.: Characterization of the human dopamine D3 receptor expressed in transfected cell lines. Eur. j Phannacol. (1994) 266(1):79–85.
   Google Scholar
• COX BA, ROSSER MP, KOZLOWSKI MR, DUWE KM, NEVE RU, NEVE KA: Regulation and functional characterization of a rat recombinant dopamine D3 receptor. Synapse (1995) 21(1):1–9.
   PubMedGoogle Scholar
• BOUTHENET ML, SOUIL E, MARTRES MP, SOKOLOFF E GIROS B, SCHWARTZ JC: Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res. (1991) 564(2):203–219.
   PubMed Web of Science ®Google Scholar
• LEVESQUE D, DIAZ J, PILON C et al.: Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 743H)1hydroxy-N,N-di-n propy1-2-aminotetralin. Proc. Nati Acad. Sri. USA (1992) 89:8155–8159.
   PubMed Web of Science ®Google Scholar
• DALY SA, WADDINGTON JL: Behavioural effects of the putative D-3 dopamine receptor agonist 7-0H- DPAT in relation to other D-2-like' agonists. Neurophannacology (1993) 32(5):509–10.
   PubMedGoogle Scholar
• SVENSSON K, CARLSSON A, WATERS N: Locomotor inhibition by the D3 ligand R (+) 7 OH DPAT is independent of changes in dopamine release. I Neural. Transm. Gen. Sect. (1994) 95(1):71–74.
   PubMedGoogle Scholar
• ACCILI D, FISHBERG CS, DRAGO J et al.: A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc. Nati Acad. Sri. USA (1996) 93(5):1945–1949.
   PubMedGoogle Scholar
• XU M, KOELTZOW TE, SANTIAGO GT etal.: Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron (1997) 19(4) :837–848.
   Google Scholar
• MENALLED LB, DZIEWCZAPOLSKI G, GARCIA MC, RUBINSTEIN M, GERSHANIK OS: D3 receptor knockdown through antisense oligonucleotide administration supports its inhibitory role in locomotion. Neuroreport (1999) 10(15):3131–3136.
   PubMedGoogle Scholar
• LUNDSTROM K, TURPIN MP: Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochern. Biophys. Res. Commun. (1996) 225(3):1068–1072.
   PubMed Web of Science ®Google Scholar
• LAND WEHRMEYER B, MENGOD G, PALACIOS JM: Dopamine D3 receptor mRNA and binding sites in human brain. Mol. Brain Res. (1993) 18:187–192.
   PubMedGoogle Scholar
• LEVANT B: The D3 dopamine receptor: neurobiology and potential clinical relevance. Phannacol. Rev (1997) 49:231–252.
   PubMedGoogle Scholar
• SCHMAUSS C, HAROUTUNIAN V, DAVIS KL AND DAVIDSON M: Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc. Natl. Acad. Sri. USA (1993) 19:8942–8946.
   Google Scholar
• CAINE SB, KOOB CF: Modulation of cocaine self-administration in the rat though D3 dopamine receptors. Science (1993) 260: 1814-1816.
   Google Scholar
• STALEY JK, MASH DC: Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. Neurosci (1996) 16:6100–6106.
   Google Scholar
• CUMMINGS JL: D3 receptor agonists: combined action neurological and neuropsychiatric agents. I Neural. Sri. (1999) 163:2–3.
   PubMedGoogle Scholar
• SZEGEDI A, HILLERT A, WETZEL H et al.: Pramipexole, a dopamine agonist in major depression: antidepressant effects and tolerability in an open label study with multiple doses. Glitz Neurapharmacal. (1997) 20:S36–S45.
   Google Scholar
• GONZALEZ AM, SIBLEY DR: 13H1-0H-DPAT is capable of labeling dopamine D2 as well as D3 receptors. Eur. Pharinacal (1995) 272:R1–R3.
   Google Scholar
• GRIFFON N, SAUTEL F, PILON C et al.: Functional models for the dopamine D3 receptor. Biachein. Soc. Transit. (1996) 24:193–198.
   PubMedGoogle Scholar
• PUGSLEY TA, DAVIS MD, AKUNNE HC et al.: Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. Pharinacal. Exp. Ther. (1995) 275(3):1355–1366.
   PubMedGoogle Scholar
• STEINER H, FUCHS S, ACCILI D: D3 dopamine receptor-deficient mouse: evidence for reduced anxiety. Physial Behav (1998) 63:137–141.
   Google Scholar
• GILBERT DB, MILLAR J, COOPER SJ: The putative dopamine D3 agonist, 7-0H-DPAT, reduces dopamine release in the nucleus accumbens and electrical self-stimulation to the ventral tegmentum. Brain Res. (1995) 681(1-2), 1–7.
   PubMedGoogle Scholar
• SMITH AG, NEILL JC, COSTALL B: The dopamine D3/D2 receptor agonist 7-0H-DPAT induces cognitive impairment in the marmoset. Pharinacal. Biachein. Behav. (1999) 63:201–211.
   PubMedGoogle Scholar
• •Study demonstrating that activation of dopamine D3 receptors produces a selective impairment of aspects of cognitive function in the marmoset.
   Google Scholar
• HUBBLE JP: Pre-clinical studies of pramipexole: clinical relevance. Eur. Neural (2000)7 (Suppl. 1):15–20.
   Google Scholar
• GUTMAN M, JASKOLKA J: The use of pramipexole in Parkinson's disease: are its actions on D3 mediated? Parkinsonism and Related Disorders (2001) 7:231–234.
   PubMedGoogle Scholar
• •Review of the mechanism of action of Pramipexole in the treatment of PD.
   Google Scholar
• LAGOS E SCORZA C, MONTI JM et atEffects of the D3 preferring dopamine agonist pramipexole on sleep and waking, locomotor activity and striatal dopamine release in rats. Eur. Neuropsychapharmacal (1998) 8:113–120.
   PubMedGoogle Scholar
• ••Study demonstrating pramipexole induceddose-related effects on sleep and waking in rats.
   Google Scholar
• CHU E, CHU T-C POTTER DE: Mechanisms and sites of ocular action of 7-Hydroxy-2-dipropylaminotetralin: A dopamine3 receptor agonist. j Pharmacy]. Exp. Ther. (2000) 293:710–716.
   PubMedGoogle Scholar
• •Demonstrates the mechanism of action of 7-0H-DPAT on intraocular pressure and aqueous humor flow rate in New Zealand white rabbits.
   Google Scholar
• FINK-JENSEN A, NIELSEN EB, HANSEN L, SCHEIDELER MA: Behavioral and neurochemical effects of the preferential dopamine D3 receptor agonist as-8-0H-PBZI. Eur. j Pharmacy]. (1998) 342:153–161.
   PubMedGoogle Scholar
• •Demonstrates that cis-8-0H-PBZI, a preferential dopamine D3 receptor agonist in vitro, exhibits an in vivo profile suggestive of antipsychotic efficacy with low catalepsy potential.
   Google Scholar
• WITKIN J, GASSIOR M, ACRI J: Atypical antipsychotic-like effects of the dopamine D3 receptor agonist, (+)-PD 128, 907. Eur. j Pharmacy]. (1998) 347:R1–R3.
   Google Scholar
• •Demonstrates that the D3 agonist PD 128907 possess an atypical antipsychotic profile in a mouse model of antipsychotic drug efficacy.
   Google Scholar
• WUSTROW D, BELLIOTTI T, GLASE S et al: Aminopyridines with high affinity for both serotonin and dopamine receptors. Med. Chem. (1998) 41(5):760–771.
   Google Scholar
• ZOSKI KT, AKUNNE HC, GEORGIC LM et al.: Receptor binding and functional characterization of the D2/D3/5-HT1A partial agonist PD 158771, a potential antipsychotic. Soc. Neurosci. (1996) Abstracts 22:1188.
   Google Scholar
• HORNYKIEWICZ 0: Biochemical aspectsof Parkinson's disease. Neurology (1998) 51:S2–S9.
   PubMed Web of Science ®Google Scholar
• RY00 HL, PIERROTTI D, JOYCE JN:Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease. Mov. Disease (1998) 13:788–797.
   PubMedGoogle Scholar
• JOYCE JN, RY00 H, GUREVICH EV, ADLER C, BEACH T: Ventral striatal D3 receptors and Parkinson's disease. Parkinsonism and Related Disorders (2001) 7:225–230.
   PubMedGoogle Scholar
• •Report discussing the reduction of D3 receptors in PD.
   Google Scholar
• PERACHON S, SCHWARTZ JC, SOKOLOFF P: Functional potencies of new antiparkinsonian drugs at recombinant human D1, D2 and D3 receptors. Eur. Pharmacy]. (1999) 366:293–300.
   PubMed Web of Science ®Google Scholar
• SVENSSON K, CARLSSON A, HUFF RIVI, KLING-PETERSEN T, WATERS N: Behavioral and neurochemical data suggest functional differences between D2 and D3 receptors. Eu.rj Pharmacy]. (1994) 263: 235–243.
   PubMed Web of Science ®Google Scholar
• CARVEY PM, MCGUIRE SO, LING ZD: Neuroprotective effects of D3 dopamine receptor agonists. Parkinsonism and Related Disorders (2001) 7:213–223.
   PubMed Web of Science ®Google Scholar
• •Manuscript reviewing the concept of neuroprotective effects of D3 receptor agonists in the context of tissue culture strategies of neuroprotection.
   Google Scholar
• KITAMURA Y, KOSAKA T, KAKIMURA JI et al.: Protective effects of the antiparkinsonian drugs talipexole against 1-methy1-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mal Pharmacy]. (1998) 54:1046–1054.
   PubMed Web of Science ®Google Scholar
• Diagnostic and statistical manual of mentaldisorder, 4th ed. Acmerican Psychiatric association,Washington DC, USA (1994).
   Google Scholar
• GITTELMAN R, MANNUZZA S, SHENKER R, BONAGURA N: Hyperactive boys almost grown up. I. Psychiatric status. Arch. Len. Psychiatry (1985) 42(10):937–947.
   Google Scholar
• MANNUZZA S, KLEIN RG, ADDALLI KA: Young adult mental status of hyperactive boys and their brothers: a prospective follow-up study. j Am. Acad. Child Adolesc. Psychiatry (1991) 30(5)743–751.
   Google Scholar
• LEVY F, BARR C, SUNOHARA G: Directions of aetiologic research on attention deficit hyperactivity disorder. Aus. NZI Psychiatry (1998) 32(1):97–103.
   PubMed Web of Science ®Google Scholar
• FARAONE SV, BIEDERMAN J, MONUTEAUX MC: Toward guidelines for pedigree selection in genetic studies of attention deficit hyperactivity disorder. Genet. Epidemial (2000) 18(1):1–16.
   PubMedGoogle Scholar
• VAIDYA CJ, AUSTIN G, KIRKORIAN G et al: Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proc. Natl. Acad. Sci. USA (1998) 95(24):14494–14499.
   PubMed Web of Science ®Google Scholar
• COOK EH, JR., STEIN MA, KRASOWSKI MD et al.: Association of attention-deficit disorder and the dopamine transporter gene. Am. I Hum. Genet. (1995) 56(4):993–998.
   Google Scholar
• GILL M, DALY G, HERON S, HAWI Z, FITZGERALD M: Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mal Psychiatry (1997) 2(4):311–313.
   PubMedGoogle Scholar
• FARAONE SV, BIEDERMAN J, WEIFFENBACH B et al: Dopamine D4 gene 7-repeat allele and attention deficit hyperactivity disorder. Am. j Psychiatry (1999) 156(5):768–770.
   PubMed Web of Science ®Google Scholar
• LAHOSTE GJ, SWANSON JM, WIGAL SB et al.: Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol. Psychiatry (1996) 1(2):121–124.
   PubMed Web of Science ®Google Scholar
• SMALLEY SL, BAILEY JN, PALMER CG et al: Evidence that the dopamine D4 receptor is a susceptibility gene in attention deficit hyperactivity. Mal Psychiatry (1998) 3(5):427–430.
   PubMedGoogle Scholar
• ROWE DC, STEVER C, GIEDINGHAGEN LN et al: Dopamine DRD4 receptor polymorphism and attention deficit hyperactivity disorder. Mal Psychiatry (1998) 3(5):419–426.
   PubMedGoogle Scholar
• CAINE SB, KOOB GF, PARSONS LH, EVERITT BJ, SCHWARTZ JC, SOKOLOFF P: D3 receptor test in vitro predicts decreased cocaine self-administration in rats. Neuroreport (1997) 8:2373–2377.
   PubMedGoogle Scholar
• NADER MA, MACH RH: Self- administration of the dopamine D3 agonist 7-0H-DPAT in rhesus monkeys is modified by prior cocaine exposure. Psychopharmacology (1996) 125(1):13–22.
   PubMedGoogle Scholar
• LAMAS X, NEGUS SS, NADER MA, MELLO NK: Effects of putative dopamine D3 receptor agonist 7-0H-DPAT in rhesus monkeys trained to discriminate cocaine from saline. Pschychopharmacology (Berl) (1996) 124:306–314.
   PubMedGoogle Scholar
• SPEALMAN RD: Dopamine D3 receptor agonists partially reproduce the discriminative stimulus effects of cocaine in squirrel monkeys. j Pharmacol. Exp. Ther. (1996) 278:1128–1137.
   PubMedGoogle Scholar
• BAXTER LR et al: Localization of neurochemical effects of cocaine and other stimulants in the human brain. j Chu. Psychiatry (1988) 49:23–26.
   PubMedGoogle Scholar
• CHILDRESS AR et al: Regional brain blood flow during induced cocaine craving. Soc. Neurosci Abstr. (1994) 20:1632.
   Google Scholar
• VOLKOW ND, FOWLER JS, WANG GJ: Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. I Psychopharmacol (1999) 13(4)337–345.
   Google Scholar
• GRANT S et al.: Activation of memory circuits during cue-elicited cocaine craving. Proc. Natl. Acad. Sci. USA (1996) 93:12040–12045.
   PubMed Web of Science ®Google Scholar
• WISE RA: Neurobiology of addiction. Curl: Opin. Neurobiol (1996) 6:243–251.
   PubMed Web of Science ®Google Scholar
• ROBERTS DCS, RANALDI R: Effect of dopaminergic drugs on cocaine reinforcements. Chu. Neuropharmacol (1995) 18:S84–S95.
   Google Scholar
• PILLA M, PERACHON S, SAUTEL F et al.: Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature (1999) 400:371–375.
   PubMed Web of Science ®Google Scholar
• ••Report of the effect of the first D3 receptorselective agonist on inhibition of cocaine-seeking behaviour in rodent model.
   Google Scholar
• WHITELAW RB et al.: Excitotoxic lesions of the basolateral amygdala impair the acquisition of cocaine-seeking behaviour under a second-order schedule of reinforcement. Psychopharmacology (1996) 127:213–214.
   PubMed Web of Science ®Google Scholar
• HITCHCOTT PK, PHILLIPS GD: Effectsof intra-amygdala R(+) 7-0H-DPAT on intra-accumbens d-amphetamine-associated learning. II. Instrumental conditioning. Psychopharmacology (1998) 140(3):310–318.
   PubMedGoogle Scholar
• WEISS E MARKOU A, LORANG MT, KOOB GF: Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. Brain Res. (1992) 593:314–318.
   PubMedGoogle Scholar
• WOOD MD, BOYFIELD I, NASH DJ, JEWITT FR, AVENELL KY, RILEY GJ: Evidence for antagonist activity of the dopamine D3 receptor partial agonist, BP 897, at human dopamine D3 receptor. Eur. Pharmacol. (2000) 407:47–51.
   PubMedGoogle Scholar
• ••Interesting study using microphysiometryand radioligand binding, demonstrating that at both human dopamine D3 abd D2 receptors, BP 897 lacked agonist activity but was a potent and selective D3 antagonist.
   Google Scholar
• COOK CD, RODEFER JS, PICKER MJ: Selective attenuation of the antinociceptive effects of mu opioids by the putative dopamine D3 agonist 7-0H-DPAT. Psychopharmacology (1999). 144(3)239–247.
   Google Scholar
• GRANDJEAN P: Restless legs syndrome.Report of experience. Schweizerische Rundschau fur Medizin Praxis (1993) 82(43):1195–1197.
   Google Scholar
• MONTPLAISIR J, DENESLE R, PETIT D: Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur. Neurology (2000) 7\(Suppl. 1):27–31.
   Google Scholar
• ROSEN RC: Sexual pharmacology in the 21sl Century. j Gender-Specific Med. (2000) 3(5):45–52.
   PubMedGoogle Scholar
• MAJ J, ROGOZ Z: Synergistic effect of pramipexole and sertraline in the forced swimming test. Polish I Pharmacol (1999) 51(6):471–475.
   PubMedGoogle Scholar
• •Preclinical study demonstrating a synergistic effect of pramipexole and SSRI in the forced swilling test in rats.
   Google Scholar
• SPORN J, GHAEMI SN, SAMBUR MR et al.: Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Annals of Chu. Psychiatry (2000) 12(3):137–140.
   PubMedGoogle Scholar
• WAGNER ML, WALTERS AS, COLEMAN RG, HENING WA, GRASING K, CHOKROVERTY S: Randomized, double-blind, placebo-controlled study of clonidine in restless legs syndrome. Sleep (1996) 19(1):52–58.
   PubMedGoogle Scholar
• SVENSSON K, ERIKSSON E, CARLSSON A: Partial dopamine receptor agonists reverse behavioral, biochemical and neuroendocrine effects of neuroleptics in the rat: potential treatment of extrapyramidal side effects. Psychopharmacology (1993) 37(10):1037–1045.
   Google Scholar
• RIFFEE WH, WILCOX RE: Effects of multiple pretreatment with apomorphine and amphetamine on amphetamine-induced locomotor activity and its inhibition by apomorphine. Psychopharmacology (1985) 85(1):97–101.
   PubMedGoogle Scholar
• MEIL WM, SEE RE: Lesions of the basolateral amygdala abolish the ability of drug associated cues to reinstate responding during withdrawal from self-administered cocaine. Behav. Brain. Res. (1997) 87:139–148.
   PubMed Web of Science ®Google Scholar
• DE BOER P, ENRICO P, WRIGHT J et al.: Characterization of the effect of dopamine D3 receptor stimulation on locomotion and striatal dopamine levels. Brain Res. (1997) 758:83–91.
   PubMedGoogle Scholar
• OUAGAZZAL AM, CREESE I: Intra-accumbens infusion of D3 receptor agonists reduces spontaneous and dopamine-induced locomotion. Pharmacol. Biochem. Behav. (2000) 67:637–645.
   PubMedGoogle Scholar
• ••Excellent study designed to characterise thebehavioural effects induced by local infusion of PD 128907 & 7-0H-DPAT into the nucleus accumbens. It also discusses the possibility that a population of postsynaptic dopamine receptors might mediate suppression of locomotion.
   Google Scholar
• BARTOSZYK GD: Anxiolytic effects of dopamine receptor ligands: I. Involvement of dopamine autoreceptors. Life Sci. (1998) 62:649–663.
   Google Scholar
• GENDREAU PL, PETITTO JM, PETROVA A, GARIEPY JL, LEWIS MH: D3 and D2 dopamine receptor agonists differentially modulate isolation-induced social-emotional reactivity in mice. Behavioural Brain Res. (2000) 114:107–117.
   PubMedGoogle Scholar
• ••This study demonstrates that D3 and D2receptors differentially modulate the expression of social emotion reactivity. A first step in the identification of relationships between dopamine receptor subtypes and specific social emotional behavior.
   Google Scholar
• MONTPLAISIR J, NICOLAS A, DENESLE R, GOMEZ-MANCILLA B: Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology (1999) 52(5):938–943.
   PubMed Web of Science ®Google Scholar
• ROSENBAUM JF, FREDMAN SJ: Pramipexole treatment for cocaine cravings. Am.j Psychiatry (1999) 156(11)1834.
   Google Scholar
• CONTIN M, RIVA R, ALBANI F, BARUZZI A: Pharmacokinetic optimisation of dopamine receptor agonist therapy for Parkinson's disease. CNS Drugs (2000) 14(6):439–455.
   Google Scholar
• CORBIN AE, MELTZER LT, NINTEMAN FW et al.: PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT1A agonist actions: Preclinical behavioral effects. Neurophannacology (2000) 39:1211–1221.
   PubMedGoogle Scholar
• •Describes the profile of the D2/D3 partial agonist PD 158771 in rodent and primate behavioural models.
   Google Scholar